Jeff Elton, ConcertAI CEO (via MassBio)

Con­cer­tAI sings a uni­corn tune as the FDA-part­nered clin­i­cal tri­als soft­ware up­start ex­pands

The crescen­do is build­ing at Con­cer­tAI as the ar­ti­fi­cial in­tel­li­gence life sci­ences start­up reels in its en­sem­ble to boost clin­i­cal study di­ver­si­ty, ex­pand de­cen­tral­ized clin­i­cal tri­als and pile on the re­al-world da­ta for can­cer treat­ments.

The FDA-part­nered up­start raised a $150 mil­lion Se­ries C, soar­ing in­to uni­corn sta­tus to a $1.9 bil­lion val­u­a­tion, to take its tech on a world­wide tour. The cur­rent set list of 45 bio­phar­ma and con­tract re­search or­ga­ni­za­tion cus­tomers is not enough for the five-year-old Cam­bridge, MA, com­pa­ny.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.